This year will be a period most investors would soon rather forget, as virtually all international stock markets suffered significant losses due to the current global economic crisis. For the year, the Dow Jones World Index fell approximately 43%, despite international efforts to lower interest rates and increase spending through massive bailout plans. The credit freeze debilitated corporate and consumer spending adversely affecting all commerce across every major economy. Not surprisingly, all four IBO Stock Indexes reported significant losses along with the rest of the world markets.

Following several years of positive returns, all four IBO Stock Indexes were sharply lower in 2008. The Diversified Instrumentation Stock Index fell 41.0% to lead all IBO Stock Indexes lower, while the Laboratory Instrumentation and Process/Metrology/Motion Instrumentation Stock Indexes followed closely behind, with losses of 40.5% and 38.9%, respectively. The Lab Consumables/Equipment Index sustained the smallest loss despite falling 27.9%.

US Stock Indexes

In 2008, the US stock markets reported the largest decline since the Great Depression, as the Dow Jones Industrial Average, S&P 500 and NASDAQ fell 33.8%, 38.5% and 40.5%, respectively. The economic contraction spurred by speculative investments, excess credit and unregulated derivatives ultimately led to the failure of well-known financial and insurance companies, such as AIG, Fannie Mae, Freddie Mac, Bear Stearns, Merrill Lynch and Lehman Brothers. If not for the unprecedented infusion of capital by the government, the list of companies and industries may have been much longer. Going forward, the current economic outlook remains distressed as the US will face many similar economic issues in 2009, including rising unemployment, housing foreclosures, strict lending and lower consumer spending. However, the equity markets may resurface as the alternatives for investments dwindle.

Gainers & Losers

This year’s list of the top five gainers and decliners among the four IBO Stock Indexes is comprised of the 43 companies in IBO’s stock table (see page 5). Only two companies managed to post positive returns for the year: Sequenom, which was the third-best performer in 2007, and Luminex. Both companies sparked investors’ interest with the development of new molecular diagnostics tests. The remaining three companies to make the list of top five gainers did so by default, as they sustained the smallest losses among the companies in the Indexes.

As in 2007, the top five decliners all changed. And this year, the declines were substantially greater, with all five companies down at least 80%. Notably, all five of the bottom performers have either nano or micro market capitalization of less than $300 million. As expected, in times of economic uncertainty, investors shy away from companies of this size due to their speculative nature. However, the market capitalizations of the top four gainers were primarily small cap companies (market capitalizations between $300 million and $2 billion), which are also associated with greater risk. The exception was Illumina, which has a market cap of more than $3 billion.

Sequenom posted the largest annual stock price gain in 2008 among the companies in the IBO Stock Indexes, climbing 108%, primarily due to positive initial results for its noninvasive prenatal diagnostics tests, which have not yet been commercialized. Despite retracting 21% from its 52-week high, Luminex finished the year up 32%. The company reached various milestones including new partnerships and FDA approval for its own diagnostic assays. In addition, the company recorded record revenue, gross profit and royalty levels. CombiMatrix and Techne both escaped the year only marginally lower, down 2% and 8%, respectively, while Illumina fell 12%. CombiMatrix, which is still primarily in the development phase, introduced several diagnostics tests, including the first prostate cancer array-based test and an updated version of its pre-disposition screening test for autism. Techne withstood a majority of the selling pressure by consistently beating earnings estimates and maintaining a strong balance sheet with no debt. Sales of the company’s consumables products to hospitals and clinical and research labs remained strong, growing 18.7% in the fiscal first quarter (see IBO 12/15/08), while gross margins for these products increased to over 80% of sales. Furthermore, over the last three months, analysts’ average EPS estimate for fiscal 2009 ending June 30 for Techne increased to $2.94 from $2.90. For most of 2008, shares of Illumina were trading at record levels, as the company posted robust sales of DNA sequencers and genotyping consumables. However, the company closed the year in negative territory, down 45.6% from its 52-week high following a shortfall in third-quarter EPS and concerns over its high PE valuation.

Nanometrics recorded the sharpest decline among the Index firms, losing 88% of its value this year because of lower capital spending by the semiconductor industry. Affymetrix and X-Rite were close behind as both companies fell 87% due to lower revenues and earnings expectations. Affymetrix reported lower academic and industrial sales during the first three quarter, as sales of genome and RNA analyzers were negatively impacted by competing technologies and slower demand (see IBO 12/15/08). X-Rite suffered several setbacks following acquisitions. The company failed to comply with certain loan covenants and, as a result, was forced to sell 46.9 million common shares to reduce its debt levels.

The two remaining companies on the list of top decliners, Strategic Diagnostics and Caliper Life Sciences, fell 83% and 82%, respectively. These companies are both thinly traded and subject to extreme volatility. While Strategic Diagnostics increased revenues in the first three quarters, it reported a wider operating loss due to write-downs in inventory and sharply lower gross margins. Caliper reported lower revenues for the first three quarters and revised its full-year revenue guidance downward (see IBO 12/15/08).

Performance of the Largest Companies

This year, there was little consolation for the larger companies in the IBO Stock Indexes. Typically, large cap companies are more resistant to economic downturns. However, in 2008, the five largest IBO Index stocks by market capitalization experienced equally depressed returns. Listed in order of size, these companies are Danaher, Thermo Fisher Scientific, Agilent Technologies, Sigma-Aldrich and Roper Industries. The only new addition to the group this year was Roper, which replaced Waters. The five companies lost an average of 37% in share price in 2008.

Among the largest companies, Agilent and Thermo sustained the largest losses, falling 57% and 41%, respectively. The market caps of the two companies are $5.7 billion and $14.9 billion compared to $14.9 billion and $25.8 billion last year, respectively. Both companies lowered revenue and EPS forecasts due to economic visibility and the strengthening of the US dollar. Similarly, Danaher, which has the largest market cap at $19 billion and lost 35% of its value, revised its fourth-quarter EPS estimates, citing similar economic concerns. The two companies on the list with the smaller market caps, Roper and Sigma-Aldrich, sustained the lowest decline in value, falling 31% and 23%, respectively. Sigma-Aldrich missed third-quarter EPS estimates and Roper revised its fourth-quarter EPS guidance downward. However, both companies may have soothed investors’ concerns by paying annual dividends of $0.52 and $0.33, respectively.

Three-Year Average Growth

The sharp decline in stock prices gave back much of the gains posted over the previous two years. Looking at the performance over the past three years of the 21 companies that make up IBO’s Laboratory Instrumentation Stock Index, only seven firms showed positive returns, compared to 15 for the 2004–2007 period. Not surprisingly, the only two gainers in 2008, Sequenom and Luminex, were among the top gainers over the three-year period.

Sequenom was once again the best-performing stock among companies in the Laboratory Instrumentation Stock Index over the last three years. The company returned an average of 114% due to strong revenue growth and the development of new products. CombiMatrix, another developer of diagnostics products, returned an average of 72%, while Illumina, which was last year’s second-best performer, dropped to number three with an average gain of 55%. Rounding off the list was Luminex and Cephied, with more modest average gains of 23% and 6% a year, respectively.

Similarly, three of the top five one-year decliners in 2008, Affymetrix, X-Rite and Caliper, were also among the top five average decliners over the past three years, falling an average of 60%, 47% and 45%, respectively. The two other companies to make the list of the five largest decliners over three years, Symyx Technologies and Transgenomic, fell by an average of 40% and 25%, respectively.

International

International stock markets were similarly devalued in 2008. In Asia, Singapore’s Straits Times Index declined 49.4%, while Japan’s Nikkei 225 Index fell 42.1%. In Europe, Germany’s DAX dropped 40.4%, France’s CAC Index 40 lost 42.7%, Britain’s FTSE100 declined 31.3% and Sweden’s OMX Stockholm Exchange fell 38.8%. Outside the EU, Switzerland’s SMI Index declined 34.8%.

Following a poor performance in 2007, the international stocks in the IBO’s stock table sustained unremitting loses this year, as all 19 international companies lost value and 18 of the 19 companies declined in double digits. Horiba led all decliners among the Pacific Rim companies, falling 70%, while the remaining four companies were all lower by at least 40%.

In 2008, all 14 European companies in the IBO stock table traded lower. Genetix sustained the smallest price decline, losing only 4% of its value, while all other European companies experienced double-digit losses. Cybio declined the most, falling 80% due to lower revenues. Robotic Technology Systems declined 72% after leading all European companies lower in 2007. The company reported lower sales and increased development costs for its life science business. Horiba, Millbrook Scientific and Sartorius also fell by sizable values, declining 70%, 60%, and 58%, respectively.

In terms of average gains over a three-year period, only two international companies showed positive returns: Alpha M.O.S. and Analytik Jena, which were up 4% and 1%, respectively. The international company in IBO’s stock table that has lost the most value on average over the past three years is Robotic Technology Systems. The company reported a negative average return of 63% and has led the list of average international decliners for the last three year. The remaining companies among this year’s top five international decliners are Millbrook, Cybio, Horiba and JEOL, which were down by an average of 58%, 43%, 29% and 26%, respectively.

December

In December, the US stock markets showed momentum despite a shrinking global economy, rising unemployment and subdued consumer spending. The S&P 500 and NASDAQ gained 0.8% and 2.7%, respectively, while the Dow slipped 0.6%. Confidence was boosted by government intervention, as the Federal Reserve cut the Fed funds rate on December 16 from 1.0% to a record low of 0%–0.25%. Two days later, the government announced a $17.4 billion bailout plan for the auto industry. Also, the price of crude oil continued to fall, finishing the month down 11.2% to $44.60 a barrel. For the year, crude oil futures have declined 53% and approximately 70% from their July highs.

The Dow Jones declined 0.6% during the final month of 2008 to finish the year down 38.9% at 8,776.39. The S&P 500 improved 0.8% in December, but ended 38.5% lower at 903.25. Finally, the NASDAQ gained 2.7% , but closed the year down 40.5% at 1,577.03.

Three of four IBO Stock Index traded lower in December due to cautious analysts’ comments on a number of medical technology companies. However, the Lab Consumables/Equipment Stock Index improved 0.1%. The Laboratory Instrumentation, Diversified Instrumentation and Process/Metrology/Motion Instrumentation Stock Indexes fell 6.3%, 5.6% and 3.1%, respectively.

Laboratory Instrumentation Stock Index

In December, the Laboratory Instrumentation Stock Index fell 6.2% to finish the year down 40.5% at 390.29. Half the companies traded lower. Transgenomic led all gainers, climbing 63%, while X-Rite lost 38%. For the year, 20 companies were down, while only Sequenom and Luminex finished higher. In addition to the top five decliners previously discussed, the most notable loss in the Index was recorded by Bruker, which shed 70% of its value.

Several medical technology companies came under pressure this month following analysts’ concerns over economic conditions, including academic research budgets and changing currency exchange rates. On December 9, Deutsche Bank lowered its earnings estimates and price targets for Thermo, Illumina, Affymetrix, PerkinElmer and Waters. As if on queue, Waters lowered its fourth-quarter revenue guidance on December 11 (see IBO 12/15/08), sending shares down 11.2% the following day. The news impacted other companies, as shares of Varian, PerkinElmer, Luminex and Thermo declined 13.0%, 18.4%, 9.2% and 8.6%, respectively. On December 15, an analyst for Robert W. Baird warned of slower sales for higher-priced instruments and cut his price targets for Thermo, Illumina, Affymetrix, PerkinElmer and Waters. On the same day, Beckman Coulter reaffirmed its 2008 outlook of 12% revenue growth and EPS of $3.55–$3.65, while forecasting 5% revenue growth for 2009 on a constant-currency basis and 10% EPS growth. Shares jumped 10.8% the following day. In other news, on December 19, MOCON announced a 6% dividend increase to $0.09 per share, sending shares up 8.4%.

On December 12, following Waters’s revised outlook, both Robert W. Baird and Cowen & Company downgraded Waters to “Neutral” from “Outperform,” while Deutsche Securities downgraded the company to “Hold” from “Buy,” and Leerink Swann downgraded shares to “Market Perform” from “Outperform.” On the same day, Leerink Swann downgraded shares of Luminex to “Market Perform” from “Outperform,” and Barclays Capital downgraded Varian to “Underweight” from “Equal Weight.” On December 15, Robert W. Baird downgraded Beckman to “Neutral” from “Outperform.” Avondale initiated coverage of Cepheid with a “Market Perform” rating on December 19.

Process/Metrology/Motion Instrumentation Stock Index

The Process/Metrology/Motion Instrumentation Stock Index dropped 3.1% this month and fell 38.9% for the year to 241.87. For the month, five companies improved and three declined. RAE Systems led all decliners, dropping 45%, while Veeco Instruments gained 7%. For the year, all eight companies declined in double digits, with Nanometrics leading the way. After losing 40% of its value in 2007, ICx Technologies, the best-performing company in the Index, ended the year down 18%. On December 5, Stanford Research initiated coverage of ICx with a “Buy” rating

Laboratory Consumables/Equipment Stock Index

The Laboratory Consumables/Equipment Stock Index improved 0.1% in December with five companies gaining and two companies trading lower. Life Technologies declined the most, falling 11%, while QIAGEN improved 9%. For the year, the Laboratory Consumables/Equipment Stock Index dropped 27.9% to 364. 36, with all companies in negative territory, led by Kewaunee Scientific, which lost 54%.

On December 3, Kewaunee Scientific reported fiscal second-quarter EPS of $0.57, compared to $0.47 last year, and revenue growth of 12%, leading shares up 23.8%. Pall reported fiscal first-quarter EPS on December 9 of $0.40, $0.02 better than analysts’ expectations, but forecasted flat revenue growth for the year, sending shares down 2.6%. On December 18, Robert W. Baird downgraded Sigma-Aldrich to “Neutral” from “Outperform” and cut its price target for Life Technologies to $32 from $47.

Diversified Instrumentation Stock Index

The Diversified Instrumentation Stock Index declined 5.6% for the month and was down 41.0% to 70.47 for the year. In December, four companies declined, while Teledyne Technologies and Danaher improved 10% and 2%, respectively. Mettler-Toledo recorded the biggest loss, falling 18%. For the year, all six companies declined in double digits, led by Agilent Technologies, which fell 57%.

On December 8, Danaher cut its fourth-quarter EPS estimate by 12% to $1.03–$1.10, leading shares down 4.2% the following day. The company also reported plans to cut 1,700 jobs as part of a restructuring plan. Danaher also announced 2009 earnings expectations on December 11 of $3.70–$4.10, which was at the low range of analysts’ consensus, leading shares down 3.0%. On December 17, Agilent announced the layoff of 800 workers (see page 9), but shares were relatively unchanged. On December 22, Roper Industries lowered its fourth-quarter EPS by $0.10 to $0.73–$0.76, leading shares down 4.5%. Citigroup downgraded Roper on December 9 to “Hold” from “Buy,” sending shares down 7.5%. On December 17, Argus downgraded Danaher to “Hold” from “Buy,” yet shares traded only marginally lower. On December 12, Soleil initiated coverage of Teledyne with a “Sell” rating.

International Shares

Four Pacific Rim companies were lower in December, while Techcomp gained 24%. The worst performer was Hitachi High-Technologies, which was down 21%. For the year, all five companies were down in double-digits.

This month, eight European companies were in negative territory, five improved and Alpha MOS was unchanged. Millbrook Scientific Instruments led all decliners, falling 35%, while Spectris gained 26%.

Bar Graph: Stock Index Performance 2008

Diversified Instrumentation -41.0%

Lab Instrumentation -40.5%

NASDAQ -40.5%

Process/Metrology/Motion -38.9%

S&P 500 -38.5%

DJIA -33.8%

Lab Equip./Consumables -27.9%

Chart: IBO Instrument Industry Stock Index

Lab Instrument Stock Index S&P 500

Dec-06 539.64 340.05

Jan-07 564.40 344.83

Feb-07 537.67 337.29

Mar-07 553.46 340.66

Apr-07 568.74 355.41

May-07 576.11 366.98

Jun-07 573.08 360.44

Jul-07 584.65 348.91

Aug-07 604.22 353.40

Sep-07 648.03 366.05

Oct-07 678.52 371.47

Nov-07 654.48 355.11

Dec-07 656.46 352.05

Jan-08 583.13 330.52

Feb-08 607.77 319.03

Mar-08 600.29 317.13

Apr-08 600.29 332.20

May-08 622.99 335.75

Jun-08 602.24 306.89

Jul-08 639.07 303.86

Aug-08 643.46 307.57

Sep-08 590.45 279.64

Oct-08 456.82 232.26

Nov-08 416.63 214.88

Dec-08 390.29 216.56

Market Value 52 Week Price Change Change EPS EPS LTD/ FY R&D/

Company: Exchange (US $000s) Low High 12/31/2008 1 Month YTD P/E 12 Month FY Equity ROE Sales

Laboratory Instrumentation

Affymetrix: o $205,060 2.02 23.85 $2.99 9% -87% 9 0.33 0.17 71% 2% 20%

Beckman Coulter: n $2,826,836 35.94 77.14 $43.94 1% -40% 18 2.50 3.30 91% 15% 10%

Bio-Rad Laboratories: a $2,078,933 60.51 109.50 $75.31 2% -27% 19 4.00 3.41 52% 10% 10%

Bruker: o $670,309 3.07 17.22 $4.04 -14% -70% 9 0.46 0.59 93% 17% 11%

Caliper Life Sciences: o $46,927 0.63 5.66 $0.97 -14% -82% N/A -0.58 -0.51 9% N/A 18%

Cepheid: o $597,244 8.52 33.36 $10.38 -24% -61% N/A -0.49 -0.50 4% N/A 24%

Combimatrix: n $42,680 4.73 16.38 $7.00 -5% -8% N/A -2.38 -2.10 28% N/A 100%

Dionex: o $831,833 42.07 83.71 $44.85 -13% -46% 16 2.88 2.77 16% 27% 8%

Harvard Bioscience: o $83,804 1.70 5.19 $2.65 31% -42% N/A -0.05 -0.04 3% N/A 4%

Illumina: o $3,119,045 18.82 47.88 $26.05 18% -12% N/A -2.43 -5.14 2% N/A 20%

Luminex: o $854,443 12.57 27.00 $21.36 -3% 32% 61 0.35 -0.08 4% N/A 21%

MOCON: o $50,274 6.70 11.83 $8.82 14% -22% 12 0.72 0.67 1% 15% 7%

O.I. Corp: o $25,738 7.17 13.95 $9.98 1% -23% 33 0.30 0.20 0% 3% 12%

PerkinElmer: n $1,663,761 12.70 29.95 $13.91 -23% -47% 11 1.26 1.11 53% 8% 6%

Sequenom: o $1,172,842 5.00 29.14 $19.84 19% 108% N/A -0.73 -0.54 5% N/A 35%

Starlims: a $37,684 3.10 10.99 $4.36 19% -59% 12 0.35 0.57 11% 10% 12%

Symyx Technologies: o $200,701 2.85 12.58 $5.94 48% -23% N/A -0.37 0.56 6% 7% 53%

Thermo Fisher Scientific: n $14,939,695 26.65 62.77 $34.07 -5% -41% 15 2.20 1.76 31% 5% 2%

Transgenomic: o $21,643 0.24 0.87 $0.44 63% -19% N/A -0.08 -0.04 1% N/A 13%

Varian Inc.: o $984,088 27.32 68.69 $33.51 -8% -49% 15 2.21 2.21 11% 11% 7%

Waters: n $3,685,744 32.21 81.84 $36.65 -11% -54% 12 3.18 2.62 123% 46% 5%

X-Rite: n $43,448 1.10 11.80 $1.49 -38% -87% N/A -2.79 -0.72 19% N/A 14%

Process/Metrology/Motion Instrumentation

FEI Company: o $703,591 15.87 29.14 $18.86 -7% -24% 23 0.81 1.36 33% 12% 14%

ICx Technologies: n $271,262 3.81 9.86 $7.91 1% -18% N/A -0.45 -2.85 N/A N/A 15%

MTS Systems: o $456,237 21.12 43.88 $26.64 2% -38% 10 2.80 2.80 4% 24% 4%

Nanometrics: o $21,174 0.80 9.93 $1.14 1% -88% N/A -4.38 -0.22 15% N/A 13%

RAE Systems: n $32,270 0.39 2.81 $0.54 -45% -80% N/A -0.10 -0.18 18% N/A 9%

Strategic Diagnostics: o $18,152 0.71 5.42 $0.89 -9% -83% N/A -0.15 0.04 0% 2% 11%

Veeco Instruments: o $199,444 3.53 19.82 $6.34 7% -62% N/A -0.27 -0.56 45% N/A 15%

Zygo: o $118,589 4.66 13.79 $6.91 5% -45% 46 0.15 0.07 2% 1% 15%

Lab Consumables/Equipment

Kewaunee Scientific: o $23,084 6.50 20.09 $9.01 2% -54% 6 1.44 1.23 21% 12% 0%

Life Technologies: o $4,041,301 19.56 49.00 $23.31 -11% -50% 12 1.90 1.83 71% 8% 9%

Millipore: n $2,877,083 43.36 76.92 $51.52 2% -30% 18 2.84 2.48 94% 12% 7%

Pall: n $3,426,384 21.61 43.19 $28.43 3% -29% 16 1.83 1.76 97% 19% 3%

QIAGEN: o $3,592,776 12.52 23.53 $17.56 9% -17% 46 0.38 0.28 82% 4% 10%

Sigma-Aldrich: o $5,410,944 34.33 63.04 $42.24 -2% -23% 16 2.58 2.34 25% 19% 3%

Techne: o $2,499,956 57.10 82.92 $64.52 4% -2% 23 2.80 2.64 N/A 21% 9%

Diversified Instrumentation

Agilent Technologies: n $5,658,060 14.76 38.00 $15.63 -17% -57% 8 1.87 1.87 139% 27% 12%

AMETEK: n $3,249,901 27.32 53.12 $30.21 -14% -36% 12 2.46 2.12 87% 18% 5%

Danaher: n $19,096,478 47.20 88.20 $56.61 2% -35% 16 3.53 3.72 44% 15% 5%

Mettler-Toledo Int’l: n $2,340,654 60.26 115.10 $67.40 -18% -41% 12 5.65 4.70 149% 31% 5%

Roper Industries: n $4,091,436 34.85 70.48 $43.41 -5% -31% 14 3.05 2.68 103% 14% 3%

Teledyne Technologies: n $1,634,985 33.90 66.21 $44.55 10% -16% 14 3.23 2.72 74% 19% 4%

Laboratory Instrumentation Stock Index 390.29 -6.3% -40.5% 16 37% 7% 7%

Process/Metrology/Motion Instrumentation 241.87 -3.1% -38.9% 15 36% 7% 8%

Lab Consumables/Equipment Stock Index 364.36 0.1% -27.9% 17 65% 10% 3%

Diversified Instrumentation Stock Index 70.47 -5.6% -41.0% 13 72% 18% 7%

Dow Jones Industrial Average 8776.39 -0.6% -33.8%

S&P 500 903.25 0.8% -38.5%

NASDAQ Composite 1577.03 2.7% -40.5%

Price

Region Market Value Market Value 12/31/2008 Change Change EPS EPS LTD/ FY R&D/

Company (US $000s) (Local 000s) (Local) 1 Month YTD P/E 12 Month FY Equity ROE Sales

Pacific Shares

Hitachi High-Technologies: t $2,155,818 ¥195,726,735 ¥1421 -21% -42% 9 ¥152.87 ¥195.80 11% 11% 2%

Horiba: t $578,698 ¥52,540,031 ¥1237 -14% -70% 6 ¥190.64 ¥204.39 20% 11% 7%

JEOL: t $240,232 ¥21,810,633 ¥275 -2% -42% 194 ¥1.42 ¥1.42 81% 0% 7%

Shimadzu: t $1,814,443 ¥164,733,307 ¥557 -13% -45% 12 ¥46.49 ¥46.49 26% 9% 3%

Techcomp: si $36,354 SGD 25,286 $0.26 24% -46% 6 $0.04 $0.04 4% 17% 1%

European Shares

Genetix: l $520 £35,568 £0.50 16% -4% 14 £0.03 £0.03 7% 6% 8%

Millbrook Scientific Instruments: l $9 £606 £0.01 -35% -60% 30 £0.00 £0.00 6% 0% 12%

Oxford Instruments: l $1,057 £72,320 £1.49 17% -25% 29 £0.05 £0.06 94% 4% 7%

Renishaw: l $5,257 £359,575 £4.94 -7% -21% 10 £0.48 £0.48 16% 21% 18%

Robotic Technology Systems: l $25 £1,702 £0.03 -9% -72% N/A -£0.08 -£0.06 15% N/A N/A

Spectris: l $9,722 £665,005 £5.35 26% -21% 9 £0.61 £0.71 46% 28% 9%

Alpha MOS: c $12,319 € 8,850 € 3.38 0% -15% N/A -€ 0.14 -€ 0.14 11% N/A N/A

Analytik Jena: g $36,537 € 26,249 € 5.59 2% -17% 11 € 0.51 € 0.51 46% 7% 7%

Biohit: h $22,870 € 16,431 € 1.27 -16% -19% N/A -€ 0.03 -€ 0.12 74% N/A 6%

Cybio: g $5,880 € 4,224 € 0.84 -1% -80% N/A -€ 0.91 -€ 0.91 12% N/A 7%

Sartorius: g $268,837 € 193,143 € 11.33 15% -58% 8 € 1.47 € 1.78 52% 9% 7%

Tecan: s $425,731 CHF 454,382 CHF 39.0 -13% -43% 9 CHF 4.37 CHF 4.54 30% 26% 10%

Biotage: st $576 SEK 4,540 SEK 5.1 -18% -41% 6 SEK 0.87 SEK 1.12 1% 12% 12%

Exiqon: no $90,751 DKK 485,490 DKK 20.0 -9% -47% N/A -DKK 3.40 -DKK 3.35 3% N/A 59%